Collegium Pharmaceutical Inc (COLL) Expected to Post Q4 2017 Earnings of ($0.50) Per Share

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Investment analysts at William Blair dropped their Q4 2017 earnings estimates for Collegium Pharmaceutical in a report released on Monday. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings of ($0.50) per share for the quarter, down from their prior forecast of ($0.34). William Blair also issued estimates for Collegium Pharmaceutical’s Q1 2018 earnings at ($1.36) EPS, Q2 2018 earnings at ($0.35) EPS, Q3 2018 earnings at ($0.17) EPS, Q4 2018 earnings at $0.31 EPS, FY2018 earnings at ($1.09) EPS and FY2019 earnings at $1.18 EPS.

Several other analysts have also recently commented on the stock. BidaskClub cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 9th. Needham & Company LLC raised their target price on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, December 5th. They noted that the move was a valuation call. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, November 17th. Piper Jaffray Companies restated a “buy” rating and issued a $24.00 target price on shares of Collegium Pharmaceutical in a research note on Thursday, December 7th. Finally, Jefferies Group raised their target price on shares of Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, December 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Collegium Pharmaceutical has a consensus rating of “Buy” and a consensus target price of $27.17.

Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $24.37 on Wednesday. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $26.77. The company has a market cap of $769.12, a price-to-earnings ratio of -8.18 and a beta of 0.80.

In related news, CTO Alison B. Fleming sold 4,029 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the completion of the sale, the chief technology officer now owns 28,513 shares in the company, valued at $484,721. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alison B. Fleming sold 4,601 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the sale, the insider now owns 28,513 shares of the company’s stock, valued at approximately $491,849.25. The disclosure for this sale can be found here. Insiders sold 1,055,558 shares of company stock valued at $18,570,177 in the last quarter. Company insiders own 25.76% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors lifted its stake in shares of Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after purchasing an additional 2,802 shares during the period. Royal Bank of Canada lifted its stake in shares of Collegium Pharmaceutical by 12.7% in the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock valued at $365,000 after purchasing an additional 3,285 shares during the period. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Collegium Pharmaceutical by 87.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 3,500 shares during the period. Teton Advisors Inc. lifted its stake in shares of Collegium Pharmaceutical by 18.5% in the fourth quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock valued at $591,000 after purchasing an additional 5,000 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Collegium Pharmaceutical by 12.8% in the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after purchasing an additional 5,136 shares during the period. Hedge funds and other institutional investors own 82.40% of the company’s stock.

WARNING: “Collegium Pharmaceutical Inc (COLL) Expected to Post Q4 2017 Earnings of ($0.50) Per Share” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/collegium-pharmaceutical-inc-coll-expected-to-post-q4-2017-earnings-of-0-50-per-share.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply